The Rise of GLP-1 Therapies and What It Means for Clinical Supply

Over the past few years, GLP-1 receptor agonists have moved from a niche diabetes treatment to one of the most in-demand drug classes globally. Medicines such as semaglutide and tirzepatide are now widely used not only for type 2 diabetes but increasingly for obesity and metabolic disease.

Demand Is Outpacing Supply

Global demand for GLP-1 therapies has surged due to increased global trial activity involving GLP-1 comparators, expanding indications and it’s increasing availability to the wider public. As a result, supply is often:

• Subject to allocation by manufacturers

• Inconsistent across batches and pack formats

  
  

For clinical trials, this creates a clear risk, delays in sourcing can directly impact study start and continuity.

The Challenge of Sourcing at Scale

Unlike small molecule generics, GLP-1 therapies are:

• Biologic or peptide-based products requiring strict cold chain handling

• Device-based (pens/autoinjectors) with limited interchangeable formats

• Closely controlled by manufacturers and wholesalers

  
  

Sourcing large quantities especially across multiple regions requires:

• Early visibility of global availability and allocation trends

• Access to multiple supply channels

• Careful management of batch and expiry timelines

How CSI Supports Large-Scale GLP-1 Sourcing

CSI approaches GLP-1 sourcing as a supply strategy.

1. Multi-channel global sourcing: Direct manufacturer accounts, approved wholesalers, and regional partners enable access to stock across the US, EU, and APAC, reducing reliance on a single market.

2. Batch and volume planning: We work with clinical teams to forecast required volumes and secure consistent batches aligned to study timelines and regulatory requirements.

3. Cold chain and device expertise: GLP-1 products require controlled storage and transport. CSI manages:

• Temperature-controlled logistics with tracking

• Global distribution to clinical sites

  
  

4. Regulatory and documentation support: From CoAs to import/export compliance, we ensure documentation aligns with global regulatory expectations.

Planning Ahead Is Critical

With demand continuing to grow, GLP-1 availability will remain tight, and for sponsors and CROs, comparator sourcing for GLP-1 trials needs to start earlier. Early engagement with  supply partner CSI allows:

• Better access to available stock

• Reduced risk of substitutions or delays

• Greater control over study timelines

  
  

Teams that plan early with reliable sourcing partner like CSI who fits seamlessly into their supply strategy will be best positioned to keep studies on track.

Get a quote